In addition to GSH, CatB-responsive nanoDDSs demonstrate remarkable tumor-targeting precision, as exemplified by NIR-activated semiconducting PNPs that leverage CatB overexpression for selective PROTAC release [123,124]. The gene discussed is TYRP1; the disease is neoplasm.